Table 2 Kaplan-Meier analysis of GRFS at... | American Society of Hematology

Table 2

Kaplan-Meier analysis of GRFS at 1 year and adjusted GRFS for the pediatric cohort (<21 years old)

		Frequency		Survival estimate		Log rank
Factor	Strata	n	Events	Estimate	CI 95%	P value
Total conditioning*		220	105	52%	45-59
	MA	209	95	55%	49-61	<.01
	RIC	11	10	14%	1-33
Stem cell source*	Marrow-matched sibling	43	14	66%	52-80	.16
	PBSC-matched sibling	9	3	68%	38-98
	Marrow-/PBSC-matched URD	13	8	50	25-75
	Single UCB	95	45	53%	43-63
	Double UCB	60	35	43%	31-55
Gender	Male	138	67	51%	43-59	.73
	Female	82	38	54%	42-64
Diagnosis	ALL	110	51	54%	44-62	.77
	AML	72	33	54%	42-65
	MDS/MPN/CML	22	12	45%	24-64
	NHL/Hodgkin/CLL	16	9	44%	20-66
Disease risk*	Standard risk	178	80	54%	47-61	.54
	High risk	42	25	45%	31-76
CMV serostatus	Negative	91	38	58%	47-68	.17
	Positive	129	67	48%	39-56
GVHD prophylaxis	Csa or Tac with MTX	94	41	56%	46-66	.49
	Csa or Tac with MMF	124	63	49%	40-58
	Other	2	1	50%	1-91
Year of HCT*	2000-2007	136	71	47%	39-55	.09
	2008-2012	84	34	61%	51-71

		Frequency		Survival estimate		Log rank
Factor	Strata	n	Events	Estimate	CI 95%	P value
Total conditioning*		220	105	52%	45-59
	MA	209	95	55%	49-61	<.01
	RIC	11	10	14%	1-33
Stem cell source*	Marrow-matched sibling	43	14	66%	52-80	.16
	PBSC-matched sibling	9	3	68%	38-98
	Marrow-/PBSC-matched URD	13	8	50	25-75
	Single UCB	95	45	53%	43-63
	Double UCB	60	35	43%	31-55
Gender	Male	138	67	51%	43-59	.73
	Female	82	38	54%	42-64
Diagnosis	ALL	110	51	54%	44-62	.77
	AML	72	33	54%	42-65
	MDS/MPN/CML	22	12	45%	24-64
	NHL/Hodgkin/CLL	16	9	44%	20-66
Disease risk*	Standard risk	178	80	54%	47-61	.54
	High risk	42	25	45%	31-76
CMV serostatus	Negative	91	38	58%	47-68	.17
	Positive	129	67	48%	39-56
GVHD prophylaxis	Csa or Tac with MTX	94	41	56%	46-66	.49
	Csa or Tac with MMF	124	63	49%	40-58
	Other	2	1	50%	1-91
Year of HCT*	2000-2007	136	71	47%	39-55	.09
	2008-2012	84	34	61%	51-71

Denotes adjusted variable.